Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma
Resumen: The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.
Idioma: Inglés
DOI: 10.1007/s12325-016-0461-z
Año: 2016
Publicado en: ADVANCES IN THERAPY (2016), 1-18
ISSN: 0741-238X

Factor impacto JCR: 2.709 (2016)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 114 / 256 = 0.445 (2016) - Q2 - T2
Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 58 / 128 = 0.453 (2016) - Q2 - T2

Factor impacto SCIMAGO: 0.973 - Medicine (miscellaneous) (Q1) - Pharmacology (medical) (Q2)

Financiación: info:eu-repo/grantAgreement/ES/MINECO/MAT2013-43127R
Tipo y forma: Article (Published version)
Área (Departamento): Área Oftalmología (Dpto. Cirugía,Ginecol.Obstetr.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.


Exportado de SIDERAL (2020-02-21-13:31:44)

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2017-01-13, last modified 2020-02-21


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)